Data Sheet (Cat.No.T39122)

TargetMol

Inclisiran sodium

Chemical Properties

CAS No. :

Formula:

Molecular Weight:

Storage: Store at low temperature,Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Inclisiran sodium (ALN-PCSsc sodium) is a dual-strand siRNA conjugated with triantennary N-acetylgalactosamine (GalNAc), with antihypertensive activity. It inhibits the transcription of PCSK9, reducing the hepatic synthesis of proprotein convertase subtilisin/kexin type 9, and can be used in cardiovascular disease research.
Targets(IC50)	Others,Caspase,NOD-like Receptor (NLR),Pyroptosis,Interleukin,PPAR
In vitro	Inclisiran is a small double-stranded RNA molecule whose mechanism of action is to reduce PCSK-9 levels in hepatocytes by interfering with the transcription of the preprotein convertase chymotrypsin 9 (PCSK-9). This effect upregulates the expression of low-density lipoprotein (LDL) receptors on the hepatocyte membrane, ultimately leading to a decrease in circulating levels of low-density lipoprotein cholesterol (LDL-C). [1]

Solubility Information

Solubility	H2O: 4 mg/mL,Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Reference

Kosmas CE, et al. Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential. Ther Clin Risk Manag. 2020 Oct 28;16:1031-1037.

Kong N, et al. PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis. Ann Transl Med. 2022 Nov;10(22):1205.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481